New York, Feb 16, 2026, 11:17 EST — Market closed
- Johnson & Johnson ended Friday at $243.45, slipping 0.45%.
- A jury in Pennsylvania has found the company liable in the most recent baby powder talc cancer lawsuit.
- The Feb. 24 ex-dividend date is on investors’ radar, with eyes also on the quarterly update set for April 14.
Johnson & Johnson faces renewed pressure from talc lawsuits as the stock returns Tuesday, following a Pennsylvania jury’s verdict holding the company responsible in the most recent baby powder cancer case.
Shares finished Friday at $243.45, slipping 0.45%. With U.S. markets shut Monday for Presidents Day, investors have a little extra time to process the news before trading picks up again.
The halt stands out for a stock usually seen as a reliable healthcare play. Legal curveballs can rattle bets—more so when volumes are light and the week’s kickoff is already delayed.
The verdict arrives while investors are still figuring out what the so-called “endgame” on talc might be—whether it’s a settlement with a price the market can tolerate, or yet another round of trial-by-trial uncertainty that leaves the overhang unresolved.
In Philadelphia, a jury decided J&J must pay $250,000 to Gayle Emerson’s family—$200,000 of that in punitive damages aimed at punishment, not compensation—after their claim that talc-based products from the company led to her ovarian cancer. Erik Haas, J&J’s worldwide litigation head, dismissed the outcome as a “token verdict” and “meritless,” saying the company will appeal. Reuters
According to court filings seen by Reuters, this case is just one among more than 67,000 lawsuits tied to talc. J&J maintains its talc products are safe, asbestos-free, and not a cancer risk. The company ended U.S. sales of talc-based baby powder in 2020, moving to a cornstarch formula instead.
Parallel to the ongoing trials, there’s more legal maneuvering. Smith Law Firm, counsel for roughly 11,500 talc plaintiffs, has taken its own litigation funders to court, accusing them of halting a $30 million loan payment and creating what it calls a “loan to own” default—effectively a setup, the firm alleges, for the lenders to grab profits from the lawsuits. The lenders haven’t responded to requests for comment, according to Reuters. Reuters
Outside the legal battles, J&J has pushed a narrative focused on expanding its medicines and devices business. Back in January, the company projected 2026 earnings and revenue would top Wall Street’s estimates, despite anticipating a blow from a U.S. drug-pricing agreement. CEO Joaquin Duato assured analysts there’s a “line of sight” to picking up the growth pace as the decade moves forward. Reuters
Dividend-focused investors are eyeing Feb. 24. That’s when buyers must own J&J stock to snag the company’s $1.30-per-share cash dividend, set for payout on March 10 to shareholders of record as of the same Feb. 24 date. The ex-dividend date lands there, too.
The calendar points to April 14 for the next corporate update—J&J is set to report first-quarter earnings then.
The talc saga doesn’t tend to fade for long. Appeals might cut back or overturn verdicts, but a streak of unfavorable decisions — or an unexpected turn on expert evidence in federal court — has the potential to shake up assumptions about how much this could ultimately cost and when those bills might come due.
Traders have their eyes on Tuesday’s open, looking for any lagging response after Friday’s verdict. Next up: the Feb. 24 dividend cutoff, followed by the April 14 results call—that’s the next firm marker on the schedule.
